

Exceptional Eight-year Response to Stereotactic Radiosurgery Monotherapy for Multiple Brain Metastases

Ronny Kalash¹, Phillip M. Pifer², Sushil Beriwal³, Scott M. Glaser⁴, John A. Vargo³, Dwight E. Heron⁵

1. Radiation Oncology, UPMC CancerCenter 2. Department of Radiation Oncology, West Virginia University School of Medicine/Ruby Memorial Hospital 3. Department of Radiation Oncology, University of Pittsburgh Cancer Institute, UPMC 4. Radiation Oncology, City of Hope, Duarte, Ca, Usa 5. Radiation Oncology, UPMC Hillman Cancer Center

✉ **Corresponding author:** Ronny Kalash, kalashr2@upmc.edu

Disclosures can be found in Additional Information at the end of the article

Abstract

Breast cancer represents the second leading cause of brain metastases in women. Once diagnosed, brain metastases have been associated with a rapidly progressive and universally poor prognosis. Breast cancer patients, particularly those with advantageous disease characteristics, may achieve extended survival. This extended life expectancy highlights the importance of effective intracranial treatments that minimize treatment-related late toxicity.

Whole brain radiation therapy (WBRT) remains a standard of care palliative option; however, concerns remain regarding the late neurocognitive effects. Stereotactic radiosurgery (SRS) provides dose-escalated radiation therapy over a shortened course, maintaining equivalent survival and minimizing normal brain tissue exposure.

Herein, we present a breast cancer patient who demonstrated an exceptional response and remained functionally independent following 12 SRS courses targeting 14 unique brain metastases over eight years. The case illustrates the efficacy of SRS alone, as well as the comparable utility of multiple SRS treatment techniques (Gamma Knife (AB Elekta, Stockholm, Sweden), CyberKnife (Accuray, Sunnyvale, California), and TrueBeam (Varian Medical Systems, Palo Alto, California)).

Categories: Radiation Oncology, Neurosurgery

Keywords: brain metastasis, truebeam, stereotactic radiosurgery, metastatic breast cancer, cyberknife™, gamma knife radiosurgery

Received 11/14/2017

Review began 11/17/2017

Review ended 12/22/2017

Published 12/29/2017

© Copyright 2017

Kalash et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 3.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Introduction

Breast cancer remains the most commonly diagnosed malignancy and the second leading cause of brain metastasis in women [1-2]. Historically, the presence of brain metastases has been associated with a universally poor prognosis. However, breast cancer patients represent a unique cohort in which factors such as phenotype, performance status, age, and extracranial disease burden may portend an extended survival. As highlighted in the validated disease-specific graded prognostic assessment (DS-GPA), favorable subsets with HER2+/Luminal B breast cancer have a median survival of 25-27 months [3]. This extended life expectancy highlights the importance of effective intracranial treatments that minimize treatment-related late toxicity.

How to cite this article

Kalash R, Pifer P M, Beriwal S, et al. (December 29, 2017) Exceptional Eight-year Response to Stereotactic Radiosurgery Monotherapy for Multiple Brain Metastases. *Cureus* 9(12): e2001. DOI 10.7759/cureus.2001

Whole brain radiation therapy (WBRT) has routinely been used to promote intracranial control and palliate the symptoms of brain metastases. However, WBRT has been associated with risks of significant late neurocognitive decline, which can detract from the quality of life, especially in long-term survivors. Stereotactic radiosurgery (SRS) allows the delivery of highly conformal dose-escalated radiation therapy over a short time course while minimizing normal brain tissue exposure. SRS decreases the likelihood of a decline in learning and memory function as compared to WBRT while maintaining equivalent survival [4-5]. Currently, multiple SRS delivery platforms are available including Gamma Knife, linear accelerator-based therapies, and proton beam therapy. Herein, we present a breast cancer patient with multiple brain metastases with an exceptional eight-year response to SRS alone across several treatment platforms, demonstrating the efficacy of SRS alone as well as the comparable utility of multiple SRS treatment techniques (Gamma Knife (AB Elekta, Stockholm, Sweden), CyberKnife (Accuray, Sunnyvale, California), and TrueBeam (Varian Medical Systems, Palo Alto, California)).

Case Presentation

A 53-year-old woman presented with a self-palpated, biopsy-proven, invasive ductal carcinoma (estrogen/progesterone receptor positive, HER-2/neu positive) of the left breast in December 2004. She underwent neoadjuvant docetaxel/cyclophosphamide chemotherapy followed by a total mastectomy and axillary node dissection in May 2005, with pathology demonstrating ypT1N1M0 Stage IIA grade three invasive ductal carcinoma. She was subsequently treated with anastrozole and trastuzumab until three symptomatic brain metastases were discovered in June 2006. No additional distant metastases were evident. Her systemic therapy from that point included lapatinib and tamoxifen until 2010 and fulvestrant thereafter.

Over her eight-year experience with brain metastases, she received multiple courses of SRS, as outlined in Table 1. Pre-treatment magnetic resonance imaging (MRI) scans, as well as treatment fields, can be seen in Figure 1 and Figure 2. Briefly, the patient underwent surgical resection of an index left frontotemporal lesion and subsequent Gamma Knife (GK) radiosurgery to each of three metastatic sites in June 2006. A new left Sylvian fissure lesion and bilateral cerebellar lesions were treated with CyberKnife radiosurgery (CKRS) in July 2007 and March 2008, respectively. In July 2009, a new left Sylvian fissure was treated with CKRS, and in November 2010, this lesion gradually increased in size and was re-treated with CKRS. A new right parietal lobe lesion was treated with CKRS in February 2013. Three left cerebellum lesions were treated with Truebeam in December 2013. In May 2014, a new left lateral cerebellar lesion was treated with CKRS. In November 2014, the local progression of the left lateral cerebellum lesion was treated with TrueBeam radiosurgery.




FIGURE 1: Pre-SRS treatment T1-weighted post-contrast brain MRI demonstrating intracranial metastasis

Brain metastasis presenting time points include initial presentation 06/2006 (A&B), 03/2008 (C), 07/2009 (D), 02/2013 (E), 12/2013 (F), 11/2014 (G). Window (H) represents multifocal progression prior to the initiation of WBRT in 03/2015. MRI: magnetic resonance imaging; SRS: stereotactic radiosurgery; WBRT: whole brain radiation therapy.




FIGURE 2: SRS treatment fields

The 80% isodose line of SRS treatments delivered on 06/2006 (A), 11/2014 (B), 02/2013 (C), 03/2008 (D), 12/2013 (E). The whole brain course with SIB to gross disease delivered in 03/2015 is depicted in window (F). SRS: stereotactic radiosurgery; SIB: synchronous integrated boost.

Date	Treatment Site	Dose	Technique	Volume (cc)
6/15/2006	Post Op Cav + 2 Lesions	18Gy/1Fx	GammaKnife	5.20, 0.46 , 0.25
8/10/2007	Lt Sylvian Fissure	24Gy/1Fx	CyberKnife	0.51
3/27/2008	Lt Medial Cerebellar	18Gy/1Fx	CyberKnife	0.73
3/27/2008	Rt Medial Cerebellar	21Gy/1Fx	CyberKnife	1.41
7/9/2009	Lt Sylvian Fissure	24Gy/1Fx	CyberKnife	0.84
11/22/2010	Lt Lateral Cerebellar	20Gy/1Fx	CyberKnife	0.46
2/26/2013	Rt Parietal	21Gy/1Fx	CyberKnife	0.61
12/12/2013	Lt Posterior Cerebellar	18Gy/1Fx	TrueBeam	0.81
12/12/2013	Lt Medial Cerebellar	18Gy/1Fx	TrueBeam	0.32
12/12/2013	Lt Anterior Cerebellar	18Gy/1Fx	TrueBeam	0.11
5/15/2014	Lt Lateral Cerebellar	24Gy/1Fx	CyberKnife	0.18
11/23/2014	Lt Lateral Cerebellar	24Gy/3Fx	TrueBeam	2.42
3/31/2015	Whole Brain	25Gy/10Fx , 40Gy SIB	IMRT	

TABLE 1: Summary of radiation treatment from 2006 to 2015

FX: fraction; SIB: synchronous integrated boost; IMRT: intensity-modulated radiation therapy; Lt: left; Rt: right.

In March 2015, she developed dysarthric speech and an MRI discovered progressive disease in the midbrain and right temporoparietal lobe, as well as enhancement within the posterior fossa, concerning for leptomeningeal disease. She, thus, underwent a 10-fraction course of hippocampal, sparing whole brain radiation therapy. She completed each course of SRS without treatment-related toxicity, a detriment to the quality of life, and remained neurologically intact until her final intracranial progression. Six months after receiving whole brain radiation therapy, she suffered a further progression of the disease and elected to pursue hospice care.

Discussion

This case underscores the potential durable preservation of quality of life and disease control with the utilization of SRS in the treatment of a limited intracranial tumor burden. The patient underwent 12 SRS courses, targeting 14 lesions over eight years and remained functionally independent until systemic deterioration requiring hospice care. She tolerated each course of SRS without incident until eventually suffering progressive disease requiring WBRT.

Although generally very well-tolerated, the toxicity associated with SRS may include edema, seizures, and radionecrosis. RTOG 90-05 demonstrated an increased rate of neurotoxicity with increasing tumor diameter, likely secondary to increased normal tissue dose [6]. This, in combination with the single-institution series, suggests that tumor volume, rather than the number of metastases, may serve as a better gauge of the outcome when considering SRS

over WBRT [7]. The paradigm of volume rather than the number of metastases is well highlighted in the presented case, with each new presentation of an intracranial disease being of limited volume and, thus, requiring minimal normal brain tissue treatment, likely contributing to the overall exceptional outcome [8]. The total cumulative volume of disease/cavity treated by the prescription dose was 14.3 cc, yielding a low volume of normal brain tissue receiving greater than 12Gy.

GK SRS has long been a gold standard for intracranial SRS, and linear accelerator-based systems have since made significant progress. This patient received treatment via GK-SRS as well as the CyberKnife and TrueBeam platforms. Population studies demonstrate that the use of Linac-based SRS is more frequent in community settings when a cancer facility is less than 20 miles away [9]. No consistent differences in clinical efficacy have been reported between SRS platforms to date. Comparative studies have reported the shortest beam-on time with TrueBeam, and the lowest peripheral normal brain tissue dose with GK-SRS [10]. This may provide a theoretical benefit in the safety of treatment delivery and normal tissue dose. This study includes a single patient experience of each major treatment platform (GK-SRS, CKRS, and TrueBeam STX with BrainLAB), each demonstrating an excellent long-term outcome.

This patient exemplifies the excellent long-term outcome possible with SRS treatment of metastatic breast cancer. As the efficacy of systemic therapy continues to improve, the importance of SRS in the management of brain metastases will continue to grow. Currently, SRS provides efficient, effective, and less-toxic treatment of intracranial disease to promote the most desirable, long-term outcome. On-going trials will reveal the added efficacy and safety of SRS alongside systemic agents with the penetration of the blood-brain barrier.

Conclusions

SRS represents an effective treatment modality to control intracranial metastases. Multiple treatment platforms allow exceptional and equivalent long-term outcomes and may provide an improved long-term quality of life compared to whole brain radiation therapy.

Additional Information

Disclosures

Human subjects: Consent was obtained by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following:

Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. *CA Cancer J Clin.* 2005, 55:74–108. [10.3322/canjclin.55.2.74](https://doi.org/10.3322/canjclin.55.2.74)
2. DiStefano A, Yong Yap Y, Hortobagyi GN, Blumenschein GR: The natural history of breast cancer patients with brain metastases. *Cancer.* 1979, 44:1913–1918. [10.1002/1097-0142\(197911\)44:5<1913::AID-CNCR2820440554>3.0.CO;2-D](https://doi.org/10.1002/1097-0142(197911)44:5<1913::AID-CNCR2820440554>3.0.CO;2-D)
3. Sperduto PW, Kased N, Roberge D, et al.: Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. *Int J Radiation Oncol Biol Phys.* 2012, 82:2111–2117. [10.1016/j.ijrobp.2011.02.027](https://doi.org/10.1016/j.ijrobp.2011.02.027)
4. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al.: Treatment of single brain metastasis

- radiotherapy alone or combined with neurosurgery?. *Ann Neurol.* 1993, 33:583–590. [10.1002/ana.410330605](https://doi.org/10.1002/ana.410330605)
5. Brown PD, Jaeckle K, Ballman KV, et al.: Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases. *JAMA.* 2016, 4:401–409. [10.1001/jama.2016.9839](https://doi.org/10.1001/jama.2016.9839)
 6. Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J, Farnan N: Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. *Int J Radiation Oncology Biol Phys.* 2000, 47:291–298. [10.1016/S0360-3016\(99\)00507-6](https://doi.org/10.1016/S0360-3016(99)00507-6)
 7. Bhatnagar AK, Flickinger JC, Kondziolka D, Lunsford LD: Stereotactic radiosurgery for four or more intracranial metastases. *Int J Radiation Oncol Biol Phys.* 2006, 64:898–903. [10.1016/j.ijrobp.2005.08.035](https://doi.org/10.1016/j.ijrobp.2005.08.035)
 8. Flickinger JC, Schell MC, Larson DA: Estimation of complications for linear accelerator radiosurgery with the integrated logistic formula. *Int J Radiation Oncol Biol Phys.* 1990, 19:143–148. [10.1016/0360-3016\(90\)90146-B](https://doi.org/10.1016/0360-3016(90)90146-B)
 9. Park HS, Wang EH, Rutter CE, Corso CD, Chiang VL, Yu JD: Changing practice patterns of Gamma Knife versus linear accelerator-based stereotactic radiosurgery for brain metastases in the US. *J Neurosurg.* 2016, 124:1018–1024. [10.3171/2015.4.JNS1573](https://doi.org/10.3171/2015.4.JNS1573)
 10. Ma L, Nichol A, Hossain S, et al.: Variable dose interplay effects across radiosurgical apparatus in treating multiple brain metastases. *Int J CARS.* 2014, 9:1079–1086. [10.1007/s11548-014-1001-4](https://doi.org/10.1007/s11548-014-1001-4)